{
  "docId": "019de075-992f-724e-90ab-5f77d740e3ca",
  "docSlug": "2f355093e0d1610f6a0dd544c49160f7",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 33,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard 3+3 dose escalation clinical trial design for a radiopharmaceutical.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-992f-724e-90ab-5f77d740e3ca/13",
  "deckHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca",
  "deckJsonHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca.json",
  "deckAnchorHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.48,
        "x": 0.39,
        "y": 0.23
      },
      "kind": "diagram",
      "text": "Dose Escalation: 3+3 Design",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b13acc0b-59f7-4300-aa7d-1cc94e38ca89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Initial indications: Pancreatic ductal adenocarcinoma, Colorectal, Squamous cell carcinoma head & neck, Gastric, Ewings sarcoma, NED prostate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ef898c1-378b-4e1b-9668-6da6a062c0ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.52,
        "y": 0.71
      },
      "kind": "metric",
      "text": "First Patient Dosed in March 2023",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c041c656-d2d0-46d5-9755-2ed9e5bb9835",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Patients with NTSR1+ solid tumors as determined by SPECT/CT imaging",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "465165fe-aa81-477a-b0b4-1a8e505f3537",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Treatment: [225Ac]-FPI-2059 every 56 days for up to 4 cycles",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba374ee4-ddd7-486e-9d17-d5e92cefc51a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-2059 Development Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f28ab135-302a-4c5c-a3e8-6ba1dcd12424",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "3+3 dose escalation design",
      "slug": null,
      "matchId": "b8ed2865-a668-4b94-86ce-3e6e9f6b80a7",
      "evidence": "Standard clinical trial methodology for determining maximum tolerated dose",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 13,
      "from": 11,
      "beatId": "27d51353-4726-44b4-be84-702e743bbddb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "FPI-2265 Development Strategy and FPI-2059 Development Program",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}